ImmunityBio (IBRX) Competitors $4.88 -0.47 (-8.79%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IBRX vs. VCYT, TGTX, IOVA, KRYS, HRMY, SMMT, MRNA, GMAB, RDY, and PCVXShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Veracyte (VCYT), TG Therapeutics (TGTX), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Harmony Biosciences (HRMY), Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Vaxcyte (PCVX). These companies are all part of the "medical" sector. ImmunityBio vs. Veracyte TG Therapeutics Iovance Biotherapeutics Krystal Biotech Harmony Biosciences Summit Therapeutics Moderna Genmab A/S Dr. Reddy's Laboratories Vaxcyte ImmunityBio (NASDAQ:IBRX) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Do institutionals and insiders believe in IBRX or VCYT? 8.6% of ImmunityBio shares are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 1.3% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, IBRX or VCYT? ImmunityBio has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Do analysts prefer IBRX or VCYT? ImmunityBio presently has a consensus target price of $4.75, suggesting a potential downside of 2.56%. Veracyte has a consensus target price of $41.25, suggesting a potential upside of 5.23%. Given Veracyte's higher possible upside, analysts clearly believe Veracyte is more favorable than ImmunityBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Veracyte 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media prefer IBRX or VCYT? In the previous week, Veracyte had 11 more articles in the media than ImmunityBio. MarketBeat recorded 13 mentions for Veracyte and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.33 beat Veracyte's score of 0.81 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, IBRX or VCYT? Veracyte has higher revenue and earnings than ImmunityBio. Veracyte is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$7.33M463.32-$583.20M-$0.92-5.30Veracyte$361.05M8.41-$74.40M-$0.15-261.33 Is IBRX or VCYT more profitable? Veracyte has a net margin of -2.18% compared to ImmunityBio's net margin of -8,016.83%. Veracyte's return on equity of 3.02% beat ImmunityBio's return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-8,016.83% N/A -110.02% Veracyte -2.18%3.02%2.80% Does the MarketBeat Community believe in IBRX or VCYT? Veracyte received 437 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 73.13% of users gave Veracyte an outperform vote while only 16.00% of users gave ImmunityBio an outperform vote. CompanyUnderperformOutperformImmunityBioOutperform Votes416.00%Underperform Votes2184.00% VeracyteOutperform Votes44173.13% Underperform Votes16226.87% SummaryVeracyte beats ImmunityBio on 12 of the 19 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.40B$2.94B$5.05B$8.82BDividend YieldN/A1.89%5.17%4.07%P/E Ratio-5.3044.65123.8917.66Price / Sales463.32359.351,181.4274.22Price / CashN/A160.0933.6632.53Price / Book-5.543.734.684.68Net Income-$583.20M-$41.63M$119.38M$226.08M7 Day Performance0.93%-7.92%-2.46%-2.03%1 Month Performance37.32%-7.14%-4.07%0.07%1 Year Performance20.37%23.06%29.77%24.61% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio0.735 of 5 stars$4.88-8.8%$4.75-2.6%+20.4%$3.73B$620,000.00-5.30590Positive NewsVCYTVeracyte4.1264 of 5 stars$39.20+0.1%$41.25+5.2%+50.5%$3.03B$361.05M-261.33790Analyst ForecastTGTXTG Therapeutics4.2148 of 5 stars$31.15+2.7%$37.67+20.9%+143.0%$4.85B$233.66M-311.47290Positive NewsIOVAIovance Biotherapeutics4.0443 of 5 stars$8.14-0.6%$22.33+174.4%+48.3%$2.48B$1.19M-5.46500Options VolumeKRYSKrystal Biotech4.8348 of 5 stars$178.10+0.1%$202.29+13.6%+70.0%$5.12B$50.70M100.62229Positive NewsHRMYHarmony Biosciences4.7841 of 5 stars$32.79+1.0%$47.00+43.3%+18.1%$1.85B$582.02M15.54200SMMTSummit Therapeutics1.863 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6286 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst RevisionGMABGenmab A/S4.3073 of 5 stars$20.45-0.2%$45.20+121.0%-37.0%$13.53B$19.84B19.852,204RDYDr. Reddy's Laboratories1.3247 of 5 stars$14.30-0.3%$17.00+18.9%+5.9%$11.94B$299.87B22.7027,048PCVXVaxcyte3.2906 of 5 stars$85.96-1.3%$147.50+71.6%+67.2%$10.85BN/A0.00160 Related Companies and Tools Related Companies VCYT Alternatives TGTX Alternatives IOVA Alternatives KRYS Alternatives HRMY Alternatives SMMT Alternatives MRNA Alternatives GMAB Alternatives RDY Alternatives PCVX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IBRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
